551 related articles for article (PubMed ID: 17168665)
21. (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer.
Crous-Masó J; Palomeras S; Relat J; Camó C; Martínez-Garza Ú; Planas M; Feliu L; Puig T
Molecules; 2018 May; 23(5):. PubMed ID: 29751678
[TBL] [Abstract][Full Text] [Related]
22. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors.
Angeles TS; Hudkins RL
Expert Opin Drug Discov; 2016 Dec; 11(12):1187-1199. PubMed ID: 27701891
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation.
Coleman DT; Bigelow R; Cardelli JA
Mol Cancer Ther; 2009 Jan; 8(1):214-24. PubMed ID: 19139131
[TBL] [Abstract][Full Text] [Related]
25. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.
Bauerschlag DO; Maass N; Leonhardt P; Verburg FA; Pecks U; Zeppernick F; Morgenroth A; Mottaghy FM; Tolba R; Meinhold-Heerlein I; Bräutigam K
J Transl Med; 2015 May; 13():146. PubMed ID: 25947066
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.
Uddin S; Jehan Z; Ahmed M; Alyan A; Al-Dayel F; Hussain A; Bavi P; Al-Kuraya KS
Mol Med; 2011; 17(7-8):635-45. PubMed ID: 21442130
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Vazquez-Martin A; Colomer R; Brunet J; Lupu R; Menendez JA
Cell Prolif; 2008 Feb; 41(1):59-85. PubMed ID: 18211286
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents.
Singh S; Karthikeyan C; Moorthy NSHN
Mini Rev Med Chem; 2020; 20(18):1820-1837. PubMed ID: 32781957
[TBL] [Abstract][Full Text] [Related]
29. Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells.
Benjamin DI; Li DS; Lowe W; Heuer T; Kemble G; Nomura DK
ACS Chem Biol; 2015 Jul; 10(7):1616-23. PubMed ID: 25871544
[TBL] [Abstract][Full Text] [Related]
30. Fatty acid synthase - Modern tumor cell biology insights into a classical oncology target.
Buckley D; Duke G; Heuer TS; O'Farrell M; Wagman AS; McCulloch W; Kemble G
Pharmacol Ther; 2017 Sep; 177():23-31. PubMed ID: 28202364
[TBL] [Abstract][Full Text] [Related]
31. Molecular Pathways: Fatty Acid Synthase.
Jones SF; Infante JR
Clin Cancer Res; 2015 Dec; 21(24):5434-8. PubMed ID: 26519059
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
[TBL] [Abstract][Full Text] [Related]
33. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
34. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
Mullen GE; Yet L
Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic MALDI-TOF Cell-Based Assay for the Discovery of Potent and Specific Fatty Acid Synthase Inhibitors.
Weigt D; Parrish CA; Krueger JA; Oleykowski CA; Rendina AR; Hopf C
Cell Chem Biol; 2019 Sep; 26(9):1322-1331.e4. PubMed ID: 31279605
[TBL] [Abstract][Full Text] [Related]
36. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity.
Brusselmans K; Vrolix R; Verhoeven G; Swinnen JV
J Biol Chem; 2005 Feb; 280(7):5636-45. PubMed ID: 15533929
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
[TBL] [Abstract][Full Text] [Related]
38. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.
Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509
[TBL] [Abstract][Full Text] [Related]
39. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis.
Menendez JA; Lupu R
Nat Rev Cancer; 2007 Oct; 7(10):763-77. PubMed ID: 17882277
[TBL] [Abstract][Full Text] [Related]
40. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]